Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
Rajendra Kumari and Gera Goverse from Crown Bioscience provide an overview of the cancer-immunity cycle and describe in vivo, in vitro, and ex vivo research tools to study immuno-oncology.
Sugar, Spice, and a Troubling Vice: Cardiovascular and Cancer Risk with Artificial Sweeteners
Artificial sweeteners appear to be the perfect solution to many of the health problems associated with high sugar consumption, but two recent publications may change the public's opinion on these sugar substitutes.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Antibody Discovery by Single B Cell Screening on Beacon®
Amy Sheng, PhD provides an overview of antibody screening platforms and presents applications and case studies using the Beacon® platform for antibody screening.
The Cancer-Immunity Cycle: Research Solutions for Preclinical Immuno-Oncology
Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.
Industry Insights with Amy Sheng on Nanobodies: An Important Tool for the Next Generation of Tumor Diagnostics and Therapeutics
Amy Sheng shares how nanobodies are emerging as important tools for tumor diagnosis and treatment.
Biomarker Imaging for Preclinical Cancer Research
Cancer biomarkers that do not cross the translational gap to clinical practice can still further research and drug discovery. In this article, we review several techniques commonly used for cancer biomarker imaging at preclinical stages, as well as recent technological advances.
Overcoming Critical Issues in Glioblastoma Multiforme (GBM) Therapeutic Development
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
Extracellular Vesicles as Breast Cancer Biomarkers
Triple-negative breast cancer is particularly aggressive, challenging to treat, and accounts for 15-20% of all breast cancers. In this blog, we review a study published in Nature Communications that examines the transforming growth factor-β targetable signaling pathway, its role in malignant cancer progression and immune suppression, and tumor-derived extracellular vesicles as diagnostic and prognostic biomarkers.
#ExpertAnswers: Bonnie Lun on Single-Domain Antibodies for Research
Dr. Bonnie Lun from Fortis Life Sciences discusses applications and advantages of using nanobodies for diagnostic and therapeutic research, and highlights Fortis/Abcore's single-domain antibody discovery services.
Single-Domain Antibodies: A Promising New Tool for Diagnostic and Therapeutic Research
Dr. Bonnie Lun answers questions about the applications and advantages of using nanobodies for diagnostic and therapeutic research.
Combination Therapy for Cancer Treatment
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.
#ExpertAnswers: Peter Ansell and Marian Navratil on Gene Expression Profiling
Peter Ansell and Dr. Marian Navratil discuss the use of novel RNA-based gene expression profiling technologies for clinical and preclinical oncology research.
Single-Domain Antibodies: A Promising New Tool for Diagnostic and Therapeutic Research
Dr. Bonnie Lun discusses applications and advantages of using single-domain antibodies for diagnostic and therapeutic research.
A Novel 3D High Throughput Co-culture System for Multiple Myeloma
During this webinar, Johannes Waldschmidt, MD, and Andreas Thomsen, MD, of the University of Freiburg in Germany, will discuss a 3D co-culture platform for the propagation of primary multiple myeloma cells ex vivo.
Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research
Dr. Peter Ansell discusses the use of novel RNA-based gene expression profiling methods for clinical and preclinical oncology research.
#ExpertAnswers: Bin Xie on Drug Development for Immuno-Oncology
Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Current and Novel Immuno-Oncology Drug Evaluation Methods via Humanized Mouse Models
Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Research Technology & Innovation Summits
The 2022 InsideScientific Research Technology & Innovation Summits focus on specific research and therapeutic areas, reviewing how novel technologies and innovative services are advancing discovery in each particular field.
Cutting Edge Conversations 2022
The Cutting Edge Conversations series offers a deep dive into specific research areas and focused insights regarding market-relevant processes from respected firms in the industry.
Cutting Edge Conversations: Discovering New Innovations in Oncology
Experts discuss progress in cancer research, including novel treatments, experimental therapies, and drug development.
